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Percutaneous 
heart valve interventions: 
a South African perspective
For nearly four decades open prosthetic valve replacement 
has been the only option for most of these patients, but in 
2000 Phillip Bonhoeffer replaced the fi rst heart valve (a pul-
monary valve) percutaneously(3) and in 2002, Cribier performed 
the fi rst percutaneous replacement of an aortic valve.(4) 
Percutaneous heart valve replacement has enjoyed a lot 
of interest with numerous new developments since then. This 
paper will discuss these developments and their relevance to 
South Africa.
BALLOON MITRAL VALVOTOMY                                 
Balloon mitral valvotomy (BMV) for rheumatic mitral stenosis 
is widely used throughout South Africa and there is considerable 
local expertise for this procedure. The technical aspects of the 
procedure are beyond the scope of this review and will not 
be discussed.
Division of Cardiology, Department of Medicine, Stellenbosch University 
and Tygerberg Hospital














INTRODUCTION                                                              
Valvular heart disease represents a signifi cant health care 
problem worldwide. More than 5 million Americans are 
diagnosed with heart valve lesions and 60 000 artifi cial valves 
are implanted annually in the USA.(1) The aetiology of valve disease 
in the developed world is predominantly degenerative. 
Research and technical advances in valve replacement surgery 
are therefore mainly focused on degenerative valve disease. 
Typical degenerative valve lesions are senile aortic stenosis 
(AS) and mitral valve regurgitation (MR) due to prolapse.
These developments may not be as relevant in the South 
African context where the aetiology of valve disease is 
frequently rheumatic and the affected patient population is 
much younger. The prevalence of rheumatic heart disease in 
South Africa is unknown; a prevalence of 0.69% has been 
reported for children, rising to 2% for children 12-14 years 
of age.(2) Rheumatic heart disease typically results in mitral 
stenosis (MS) and MR, and the latter, when present, has a 
completely different mechanism to the causes of MR mostly 
seen in developed countries.
Valvular heart disease represents a signifi cant health care 
challenge in South Africa, mainly due to the prevalence of 
rheumatic fever. This review discusses the recent advances 
in percutaneous heart valve treatment, including heart 
valve replacement, as an alternative to open prosthetic 
valve replacement and it’s relevance in South Africa.
Balloon mitral valvotomy is discussed with emphasis on 
patient selection, management during pregnancy and 
management in the presence of left atrial thrombus. 
Further developments regarding the percutaneous treat-
ment of mitral valve disease include percutaneous treatment 
of mitral incompetence by annuloplasty via the coronary 
sinus and edge-to-edge repair with the aid of a mitral clip.
Transcatheter aortic valve replacement is the more 
developed procedure and two valves have the CE mark of 
approval. Both have good short to medium term data 
demonstrating effi cacy but are technically diffi cult to 
insert, very expensive and patient selection remains a 
major problem. Their use is thus limited to patients 
turned down for conventional surgery.
Percutaneous pulmonary valve replacement has good 
evidence to show effi cacy but its use is largely limited to 





















Several studies have documented the excellent long-term out-
come of the minimally invasive BMV procedure.(5,6) In a series of 
1 024 patients followed up for a median of 49 months, the 
10-year actuarial rate for survival free of surgery or repeat 
dilatation was 67 % for the patients who had a good immediate 
result. Pre-procedural patient selection is pivotal to achieving 
a good immediate result.
The following factors were identifi ed as predictors of a poor long-
term result after BMV: 
1.  Valve factors 
fi nal mitral valve area of <1.75cm2 (relative risk 1.9);
mean gradient ≥6mmHg (relative risk 4.0); and
grade 2 MR (relative risk 1.4). (5)
2.  Clinical factors
age>70; 
NYHA class III/IV; 
previous commissurotomy; and
atrial fi brillation.(5,7)
Echocardiographic evaluation of the mitral valve is essential 
for correct patient selection. A number of scoring systems 
have been developed to improve patient selection.  The mor-
phology of the subvalvular apparatus, the presence of commis-
sural fusion and the presence of calcifi cation are included in 
most scoring systems. A well validated example is the Massa-
chusetts General Hospital Score.(8) A score of <9 in associa-
tion with no more than mild MR, is associated with a good 
short term outcome following the procedure.(9,10) 
The following clinical settings are of interest:
Pregnancy 
Mitral stenosis is a relatively common valve lesion in young 
pregnant South Africans and is poorly tolerated during the 
second and third trimester of gestation and during labour. 
Ideally, pregnancy should be postponed until after treatment of 
the valve lesion and planned in conjunction with the patient’s 
cardiologist. In South Africa, however, patients are frequently 
only seen in their mid- or last trimester with severe MS. In 








fi cant(11) and intervention should be considered. If the valve 
morphology is favourable, balloon valvotomy is performed in 
the mid trimester when the risk of radiation to the foetus is 
acceptable, provided the patient’s abdomen is shielded during 
the procedure. In a report by Sivadasanpillai, the procedure 
was performed successfully in 35/36 patients with no foetal 
or maternal mortality. Fluoroscopy time was less than 6 minutes 
in 31/36 of these cases.(12) The risk during open valve replace-
ment is low for the mother but there was a 40% fetal loss 
following open valve replacement in a study at our institution.(13) 
Combining Caesarian section and valve replacement surgery is 
no longer considered a safe option at Tygerberg Hospital due 
to concern regarding a high risk of maternal infective endo-
carditis. We have also shown that BMV can be performed 
safely during pregnancy in a study of 29 pregnant (and 29 female 
controls) patients. The procedure was successful in 97% of 
cases and the complications comparable to the non-pregnant 
group.(14) For these reasons, we consider BMV in selected 
cases with less favourable valvular morphology.  The development 
of MR post BMV remains a risk but MR is better tolerated 
in pregnancy than MS and can then be treated by valve replace-
ment surgery post partum.
Thrombus in left atrium
The American Heart Association / American College of Cardio-
logists’ guidelines for BMV require the absence of a thrombus in 
the left atrium (LA) because of the risk of embolisation.(15) 
Trans-oesophageal echo (TEE) is more sensitive than trans-
thoracic echo to screen patients for the presence a LA 
thrombus. Risk factors for the presence of thrombus includes 
older age, atrial fi brillation, LA size and smaller valve area.(16) 
Patients in whom a thrombus is detected receive anti-
coagulation therapy for 3 months. BMV can be performed safely 
once the thrombus has been resolved.(17) BMV is not performed 
in cases where the thrombus has not resolved after 3 months of 
anti-coagulation therapy, unless the patient is a poor surgical 
candidate. In a study of 313 patients, Shaw et al. found that 
thrombus limited to the LA appendage (and not protruding 
from the mouth of the appendage) was not associated with 
embolic events during BMV. Such cases at Tygerberg Hospital 
would be considered for BMV in patients who are poor 
surgical candidates on an individual basis. The presence of a 
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thrombus anywhere else in the LA is an absolute contra- 
indication to performing BMV and was supported by Shaw 
et al.’s study.(16)
 
MITRAL INCOMPETENCE                                             
Mitral valve prolapse (MVP) is the major indication for mitral 
valve surgery in developed countries, but in South Africa it 
remains a comparatively much less common indication. Mitral 
valve repair surgery is, however, performed in combination with 
coronary artery bypass grafting in patients with ischaemic mitral 
incompetence (MI). A percutaneous repair procedure is inap-
propriate in the latter setting, as the patient already requires open 
heart surgery. Surgical mitral valve repair for prolapse pathology 
is an effective procedure and any percutaneous alternative 
would have to compete with a surgical procedure with a very 
good track record.(18)
The attempts at percutaneous repair of mitral valve incompe-
tence have focused on attempting to mimic the following two 
surgical techniques: mitral valve annuloplasty and edge-to-
edge repair (so called Alfi eri stitch), neither of which addresses 
the true mechanism of MR. To date none of these devices have 
received FDA approval for use outside of an investigational 
setting. 
Mitral valve annuloplasty 
The close anatomical relationship between the coronary sinus 
(CS) and the posterior mitral valve annulus (MVA),  presents 
an apparently obvious approach to percutaneously intervene on 
the annulus. Patient selection for this procedure involves 
patients with MI and a dilated annulus. Several devices are under 
development at present. Most have a design where the device is 
anchored proximally and distally in the coronary sinus and tension 
is then applied between the two anchors to reduce the diameter 
of the annulus (Figure 1). Failure to maintain this tension has 
resulted in mechanical failure in a number of cases. In addition 
this approach has been hampered by the close proximity of 
the circumfl ex artery to the coronary sinus. Tops found that in 
68% of cases scanned with computer tomography, the circum-
fl ex artery coursed between the CS and the MVA.(19) Post 
mortem data showing that the CS is often not at the same level 
as the mitral valve annulus further reduces the appeal of 
this technique.(20)  Therefore, these devices have to date been 
tested mostly in animals. The multi-centre COMPETENT trial is 
currently enrolling humans for the insertion of the CARILLON™ 
Mitral Contour System™ (Cardiac Dimensions, Kirkland, WA.).
Edge-to-edge repair
Since Alfi eri introduced this surgical technique in 1991, a great 
deal of experience has been gained and in their hands up to 95% 
of patients do not require repeat surgery at 4 years. Edge-
to-edge repair involves suturing the central portion of the two 
mitral valve leafl ets together to create a double orifi ce. This 
prevents prolapse of the one leafl et and does not impair 
diastolic fi lling.(21) To date the Evalve Mitraclip™ (Evalve Inc., 
Menlo Park, CA) system has the most data and experience of 
the percutaneous techniques that evolved from Alfi eri’s surgical 
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FIGURE 1: Diagrammatic representation of a coronary sinus 
percutaneous mitral annuloplasty device. On the left is the 
catheter based device being inserted into the coronary sinus 
and on the right it is after deployment.
FIGURE 2: Diagrammatic representation of the Evalve Mitraclip™ 



















technique. The device consists of a surgical alloy clip covered with 
a biocompatible fabric that is attached to a delivery catheter. The 
catheter is positioned above the mitral valve via a transseptal 
puncture, passed over the valve orifi ce and then pulled back 
and closed to grasp the central portions of both leafl ets, creating 
a double orifi ce mitral valve (Figure 2). More recently, a second 
clip has been deployed if required. The guide catheter diameter 
is 24F at the skin entry and 22F at the inter-atrial septum. 
The Evalve Mitraclip™ device was tested in the EVEREST I trial 
(a multi-centre feasibility trial) where clips were implanted in 24 
patients. One month post procedure only 18 patients were 
free from surgery, but successful results were maintained at 
six months post procedure.(22) The much larger multi-centre 
EVEREST II trial planned to complete enrollment by the end 
of 2008.
The following factors could limit the future use of the above 
mentioned devices:
The complexity of the procedure and small number of referral 
centers with experience in performing the procedure. 
It will be diffi cult for the percutaneous procedures to match 
the excellent surgical results with up to 30 year follow-up data.
The regulatory approval of the devices may take too long.
An isolated edge-to-edge repair is unlikely to be suffi cient in 
patients with annulus dilatation, which represents 90% of 
cases currently referred for surgery to the Alfi eri group.(21)
This rather pessimistic view must be tempered by the fact that, 
as opposed to percutaneous aortic valve replacement (where 
patients are non-surgical candidates), the procedure can be 
offered to relatively healthy individuals. In cases where the 
procedure is unsuccessful, the clip can be explanted during an 
open repair procedure. The procedure may eventually be con-
sidered at an earlier stage to prevent the progression to left 
ventricular dysfunction. Although the device is registered in the 
US as an Investigational Device only, it received CE registration 
in 2008.
PERCUTANEOUSLY INSERTABLE MITRAL VALVE     
No percutaneous mitral valve replacements have been performed 





structure and function of the mitral valve, medical science is still 
years away from achieving success with this procedure. 
Bonhoeffer developed a percutaneous tricuspid valve consisting 
of 2 discs (similar to an ASD closure devise) which he implanted 
in seven ewes. Though successful, the stresses on this valve are 
by no means comparable to the left heart. Bonhoeffer postulated 
that a possible alternative approach is to initially surgically replace 
the valve with a prosthesis that is designed to function as a 
docking station for future percutaneous replacements. Bonhoeffer 
has tested his theory by surgically replacing mitral valves in sheep 
and then inserting a valved stent off-pump via the left atrium.(23) 
The procedure is currently not suitable for application in humans, 
but the concept may prove useful in future.
AORTIC STENOSIS                                                          
Isolated AS is typically due to degenerative changes or to con-
genital bicuspid aortic valve deformities. Many patients are 
elderly with a multitude of co-morbid conditions that increases 
the risk of open heart surgery. In Europe, up to one third of 
potential candidates are consequently not offered valve surgery. 
This is in spite of numerous advances and excellent long term 
results in aortic valve replacement surgery.(24)
Balloon valvotomy has been the initial procedure in percuta-
neous aortic valve interventions. This procedure has been 
unsuccessful due to a high rate of acute embolisation resulting 
in stroke and a high re-stenosis rate at short term (six months) 
follow-up. (25)
Transcatheter aortic valve implantation (TAVI) experiments were 
fi rst published in 1992.(26)  Bonhoeffer implanted a bovine jugular 
vein valve that was sutured onto a stent in the descending aorta 
of lambs in 2002.(27) Inserting a stented valve in the sub 
coronary position without obstructing the coronary ostia has 
proven diffi cult in animal studies.(28) In humans, however, the rim 
of calcifi ed tissue between the valve and the aortic wall probably 
acts as a barrier, preventing coronary obstruction. Since Alain 
Cribier’s fi rst human implantation in 2002, this fi eld has 
experienced exponential growth with an estimated 2 000 
implantations worldwide reported at EuroPCR08. Most of 
the current designs incorporate an expandable metal stent with 
a tissue valve sewn into it. Alternatives include infl atable 
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anchorage (which can also be defl ated and repositioned) 
(Direct Flow Medical™, Santa Rosa, CA) and a foldable, sheet 
metal stent (AorTx™, CA). A variety of tissues have been 
tested and bovine or porcine pericardium is used in the majority 
of cases. Synthetic valve cusps under development include 
polymers and fl exible metal (eNitinol utilising nanotechnology). 
Two major approaches are used with metal stents: balloon 
expandable or self expanding Nitinol stents. It is important to 
note that no valve has been approved by the FDA for use in 
humans, other than in an investigational setting. 
Numerous groups have described experience in animals and 
Grube recently published the fi rst implantation of the Sadra 
Medical Lotus valveTM.(29) This discussion will however focus on the 
designs with the most human experience.
SAPIEN VALVE                                                                 
The Cribier-Edwards™ valve (Figure 3) and its updated version, 
the Edwards-SAPIEN valve™ (Edwards Lifesciences™, Irvine 
CA) is based on Cribier’s design for the fi rst human implantation. 
The initial approach was pro-grade (via venous access and 
transseptal puncture) to aid in crossing the aortic valve. A 
major complication of this technique is that with traction, 
the catheter acts like a cheese cutter and can tear the anterior 
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mitral valve leafl et as well as the inter atrial septum.(4) More 
recent procedures have been performed via a femoral arterial 
puncture and insertion of a 24F sheath, with femoral artery 
diameter of 7-8mm as a prerequisite (depending on the size of 
the valve). As these patients tend to be elderly with frequent 
peripheral vascular disease, problematic access is an important 
contra-indication to this approach. 
The procedure may be performed under local anesthesia, but 
many experts prefer general anesthesia to enable transeso-
phageal echo monitoring. Balloon valvuloplasty is performed 
initially, which is similar to the procedure followed during Core-
Valve implantation. The crimped valve is then passed through 
the aorta to the native annulus with a steerable guiding catheter 
(Figure 4). Final position of the valve is confi rmed by fl uoroscopy, 
aortography, and where used, TEE. (30)  To attain a stable position 
in the native aortic valve orifi ce, the patients are paced at a rate 
of 180-220 bpm (and the systolic blood pressure falls to below 
60 mmHg) prior to deployment of the valve. Most groups 
could demonstrate a steep learning curve but immediate success 
rates have also increased due to refi nement of the delivery 
system.(31,32)
The trans-apical approach is used in patients with inaccessible 
femoral arteries. A small antero-lateral thoracotomy is performed 
FIGURE 3: The Cribier –Edwards™ valve. (Used with permission: 
Edwards Lifesciences™, California, USA)
FIGURE 4: Diagram illustrating deployment of a balloon 



















under general anaesthesia. The apex of the left ventricle is 
identifi ed and punctured with an arterial needle and a standard 
sheath is placed over the wire into the left ventricle through 
which the valve is deployed. Valve positioning may be easier 
than the transarterial route. The apex is surgically closed with 
pledgeted sutures and a chest tube placed.(33) To date this 
approach is only approved for the SAPIEN valve.
 
Clinical experience
The experience with the Sapien valve (and most others) has been 
exclusively in patients turned down for open valve replacement 
surgery. Cribier published a series of 27 patients with a 75% 
acute procedural success rate and immediate improvement in 
hemodynamic parameters in all successful cases. Two of the 
acute failures were due to valve migration. Signifi cant paravalvular 
aortic regurgitation (AR) was seen in 17 patients. At 30 days 
after implantation, 26% of patients had major adverse events 
(pericardial tamponade, stroke, and arrhythmia). At nine months 
after implantation only 11 patients were still alive but the majority 
of deaths were due to their comorbid conditions.(34) 
Webb published a series of 50 patients with an average Euro 
SCORE predicted mortality risk of 28%. At 30 days, their mortality 
was 16% for the initial 25 cases but decreased to 8% for the 
remaining 25. Procedural success increased from 76% for the initial 
25 cases to 96% for the last 25. The median hospital stay was 5 
days. Signifi cant improvements were demonstrated in valve area 
(from 0.6+/-0.2 cm2 to 1.7+/-0.4 cm2), LV ejection fraction 
(from 53+/-15% to 57+/-13%), mitral regurgitation grade (from 
2 to 1) and functional class. Improvement was maintained at 
one year.  Two patients suffered strokes during the procedure.(32) 
More recently they have also reported no evidence of structural 
valve deterioration beyond 2 years.(30) In the data presented 
by Martin Leon at EuroPCR 07, the average logistic Euro 
SCORE was 33% but in the 55 patients treated in the REVIVAL II 
study, 6 month mortality was only 16% (unpublished data).
With the trans-apical approach, Webb et al. described their fi rst 
seven cases with 6/7 patients alive at 3 months and signifi cant 
haemodynamic improvement in all patients.(35) In the largest 
published series of 59 cases with an average Euro SCORE 
predicted risk of 27+/-14%, Walther et al. demonstrated a 13% 
in-hospital mortality. Valve positioning was performed success-
fully in 53 patients. Four patients required early conversion to 
sternotomy and mild AR was present in 25% of cases.(36) 
Although it was initially thought that this approach would lead 
to lower risk of peri-procedural stroke, both approaches have 
a similar published stroke rate of +/-4%.(37,38)
COREVALVE REVALVING SYSTEMTM                         
The fi rst percutaneous aortic valve replacement with a self 
expanding valve was published by Grube in 2005.(39) The 
major advantage of these valves is their smaller profi le (the 
third generation Core Valve™ has a delivery sheath diameter 
of only F18) and a smaller incidence of post-procedural AR 
(mean grade of AR improved and deterioration in AR in only 5/25 
patients).(40) The prosthesis is, however, much longer than the 
Edwards-SAPIEN valve™ (50mm vs. 16mm), stretching from 
the LVOT, over the valve and aortic annulus, into the 
ascending aorta (Figure 5 and 6). Another disadvantage, due to 
the longer time required for deployment of the valve, is that 
the patients were initially all put on percutaneous cardio 
pulmonary bypass. More recently this procedure has been 
performed successfully off-pump. In their follow-up study of 86 
patients, Grube et al. included 36 cases using the 18F valve. 
In 64% of these, they could deploy the valve without hemo-
FIGURE 5: The fi rst generation CoreValve ReValving™ system. 
(Used with permission from CoreValve™) 
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dynamic support, cutting down on procedure time and cost. In 
25% of cases the procedure was performed with only local 
anesthesia to the groin and in most an arterial closure device 
was used. (41)
Clinical experience
In the most experienced centre, acute device success was 88% 
with 6 devices misplaced and 2 cases where the device would 
not cross the native valve. Overall 30-day mortality was 12% 
(mean logistic Euro SCORE was 23%).(41) Grube have now 
published their experience with all three generations of this 
device in 136 patients and demonstrated a 30-day combined 
rate of death/stroke/myocardial infarction for generation 1, 2, 
and 3 of 40.0%/20.8%/14.7% (P=0.11), with no procedural 
deaths in generation 3. Implantation success was 92% for the 
third generation device.(42) 
Despite receiving CE approval recently, the CoreValve 
ReValving™ system has not been released onto the market but 
is proceeding with an expanded clinical evaluation and is not 
available in the USA.
Patient selection for TAVI
Patient selection remains crucial but is very diffi cult. It is 
recommended that a multi-disciplinary team of cardiologists, 
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surgeons, imaging specialists and anaesthetists assess each 
patient individually. To date, the procedure is only done in 
patients with severe symptomatic AS who are turned down 
for open heart valve replacement surgery (and this should be 
the fi rst step in the evaluation). Risk scores, such as the Euro 
SCORE(43) and the STS Predicted Risk of Mortality score(44) are 
usefull. They do, however, share similar limitations. Predictive 
ability is reduced in these high-risk patients and some have 
shown that the Euro SCORE in particular tends to overestimate 
risk.(45,46) Imaging should include echocardiography and angio-
graphy of the coronary, aortic root and ileo-femoral arteries. 
CT-angiography is recommended in addition to echocardio-
graphy to evaluate the above structures, and for assessing the 
possibility of obstruction of the left main coronary artery.(30)
General contraindications for TAVI(47)  include: 
Aortic annulus < 18 or >25 mm for balloon-expandable and 
<20 or >27 for self-expandable devices;
Bicuspid valves due to the risk of incomplete deployment of 
the prosthesis;
Presence of asymmetric heavy valvular calcifi cation, which 
may compress the coronary arteries during TAVI; and
Aortic root dimension > 45 mm at the sino-tubular junction 
for self-expandable prostheses. 
Presence of apical LV thrombus.   
Contra-indications for the trans-femoral approach(47) include: 
Iliac arteries: severe calcifi cation, tortuosity, small diameter 
(<6 to 9 mm according to the device used) and previous 
aorto-femoral bypass;
Aorta: severe angulation, severe atheroma of the arch, 
coarctation and aneurysm of the abdominal aorta with 
protruding mural thrombus;
Presence of bulky atherosclerosis of the ascending aorta 
and aortic arch; and
































A large number of AS patients in South Africa have rheumatic 
involvement of the valve which is associated with mitral valve 
disease in the vast majority. The use of these new percutaneous 
procedures will therefore probably be limited to patients with 
senile degeneration of their aortic valves. 
These devices were developed for AS and their experience in 
patients with predominant AR is limited.(48) Paravalvular AR has 
been reported in most series(4,33,42,49) but with routine oversizing 
and accurate placement of the device the majority of leaks are 
mild and well tolerated 50. In vitro valve testing anticipates 
durability comparable to many conventional bio-prostheses.(30) 
Although structural valve deterioration has not been reported, 
limited late follow-up data is available.(31,38,42) Survival without 
structural failure has been reported for up to 4 years.(51)
Open surgery has an excellent track record with decades of 
follow up. No data exists to compare open surgery to TAVI in 
high risk patients. A joint statement by the ACC, AHA, STS, 
AATS and SCAI was published to outline how studies to address 
this question should be designed and controlled.(52) The 
published results come from large volume centers where 
considerable effort and funds have been invested to set up 
the procedure team. It is uncertain if this will be reproduced 
in lower volume centers.
Once these valves have been tested for longer periods and become 
commercially available, the exact role in our country will possibly 
depend on a number of factors:
Training for the procedure: Local interventionists would 
have to undergo accredited training and probably spend time 
in an accredited centre abroad. These training posts are likely 
to be extremely competitive.
Patient selection: This technology provides hope for a group 
of patients who previously had no treatment options. The 
potential for abuse/inappropriate use is, however, real and 
methods to curb this is not in place in South Africa. It is 
encouraging to see that in Europe, industry is playing a 
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leading role in the regulation of the use of their devices. One 
can only hope that a similar approach will be followed here. 
Cost: The development of percutaneous heart valves has 
been a long and expensive process and the cost of these 
valves could be prohibitively high for the majority of South 
Africans.
Cooperation between cardiologists and surgeons is crucial 
for the selection of ideal patients and technically this is a 
new fi eld for all involved. Surgeons have superior experience 
in valvular interventions and arterial cut downs, and cardio-
logists are experienced in catheter manipulation and balloon/
stent management.
PULMONARY VALVE REPLACEMENT                          
Right ventricular outfl ow tract (RVOT) reconstruction forms an 
important part of surgical correction for a wide variety of 
congenital cardiac abnormalities – most notably Tetralogy of 
Fallot and arterial switch procedures. This procedure often 
improves the haemodynamic situation dramatically despite residual 
pulmonary valve regurgitation (PR) or RVOT obstruction. These 
two residual lesions were long thought to be benign, but 
recent data has shown that they may lead to right ventricular 
dysfunction and malignant arrhythmia.(53,54) The treatment options 
for these lesions include homograft implantation, balloon 
dilatation and stenting of the RVOT.  The longevity of the fi rst 
two procedures in particular is limited by calcifi c degeneration 
resulting in re-stenosis and frequent re-intervention.(55)
Since Bonhoeffer’s fi st percutaneous pulmonary valve implanta-
tion (PPVI) in 2000, his group has performed well over a 100 
of these procedures (personal communication). They have shown 
that PPVI improves bi-ventricular performance (as measured 
by tissue Doppler, MRI) as well as exercise tolerance and 
symptoms.(56) They have also reported extensive data on 59 
patients with 9.8 (+/- 1.4) months follow-up.(57) Of the 59 
patients, 61%  had previous Tetralogy of Fallot repairs and 78% 
had a homograft conduit in the RVOT. Only 3 patients had a 




improved signifi cantly (RVOT gradient, PA pressures, RV stroke 
volume) and no patient had more than mild regurgitation post 
procedurally. Complications were classifi ed into 3 categories:
1. Complications related to balloon dilatation (dissection, 
haemorrhage or conduit rupture and residual stenosis) – 
fortunately very rare.
2. Patient selection – patients had varied RVOT anatomies and, 
for regurgitant lesions, dislodgement was a problem. More 
recent imaging modalities will reduce this complication.
3. Device design – stent fracture and acute in-stent stenosis due 
to protrusion of the vessel wall lead to modifi cations of 
the design which should reduce these problems.
Despite the above problems, there were no fatalities and in a 
number of patients, complications could be managed by 
deploying a second valve within the faulty one.
The patent for this design was acquired by the Medtronic™ 
Corporation who launched it as the Melody™ Transcatheter 
Pulmonary valve. Although not available for sale in the USA at 
the time of this review, it has received the CE Mark approval 
for distribution in Europe. According to the package insert, 
intended lifetime of this device is 2 years.
One can conclude that the future is (almost) here, but that 
South Africans would probably have to wait a bit longer. Issues 
that need to be addressed are cost, adequate training and 
regulation.
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